, opens new tab will sell its remaining 9.5% stake in the company, about a year after the healthcare conglomerate spun off and listed its consumer health business. Based on Kenvue stock's last ...
Tylenol maker Kenvue has said that Johnson & Johnson will sell its remaining 9.5% stake in the company, about a year after the healthcare conglomerate spun off and listed its consumer health business.
J&J to exit Kenvue, a year after spinoff Story by Reuters • 8h (Reuters) - Tylenol maker Kenvue said on Monday that Johnson & Johnson will offload its entire 9.5% stake in the company, ...
Kenvue's shares were down 1.2% in premarket trading. J&J shares were largely unchanged. J&J finalized the biggest shake-up in its 137-year history to focus on its pharmaceutical and medical ...
(Reuters) – Tylenol maker Kenvue said on Monday that Johnson & Johnson will offload its entire 9.5% stake in the company, about a year after the healthcare conglomerate spun off and listed its ...
(Reuters) -Tylenol maker Kenvue said on Monday that Johnson & Johnson will sell its remaining 9.5% stake in the company, about a year after the healthcare conglomerate spun off and listed its consumer ...
(Reuters) – Tylenol maker Kenvue said on Monday that Johnson & Johnson will offload its entire 9.5% stake in the company, about a year after the healthcare conglomerate spun off and listed its ...